First, Wohua Medicine
Wohua Medicine established Weifang Chinese Medicine Factory in Shandong Province on the basis of 1959 1. In February 2002, it was restructured into Weifang Wohua Pharmaceutical Technology Co., Ltd. ... On June 24, 2007, the company's shares were officially listed on the Shenzhen Stock Exchange, becoming the first listed pharmaceutical enterprise in Weifang.
Second, Sinopharm shares
Sinopharm Holdings Pharmaceutical Co., Ltd. was successfully listed on Shanghai Stock Exchange on October 27th, 2002. Sinopharm Group Pharmaceutical Co., Ltd. was established by China Pharmaceutical Group Company. Approved by the State Economic and Trade Commission, it was formally established on199965438+February 2 1.
Third, Shanghai medicine
Shanghai pharmaceutical group co., ltd (stock code: 60 1607) is a state-owned pharmaceutical industry group headquartered in Shanghai. It is one of the few listed pharmaceutical companies in China that is in a leading position in the pharmaceutical products and circulation market, and has been selected as sample stocks of Shanghai Stock Exchange 180 Index and Shanghai and Shenzhen 300 Index.
Extended data:
Industry scale of pharmaceutical stocks:
1, the data shows that the pharmaceutical industry ushered in a strong recovery in 20 13. From 20 13 to 1-2 months, the pharmaceutical manufacturing industry realized a total income of 272.4 billion yuan, a year-on-year increase of 22.7%; The accumulated total profit was 25.74 billion yuan, a year-on-year increase of 24.30%, and the growth rate of main business income and total profit reached a new high.
2. It is particularly worth mentioning that 1 1 month before 20 12, when the year-on-year growth rate of total profit was lower than that of main business income, the data of 12 and 10-02 both reversed, and the recovery momentum of the pharmaceutical industry was obvious. However, the foreign trade of drugs continued the previous growth trend. In the first two months, the import and export amounted to US$ 65.438+02.635 billion, a year-on-year increase of 654.38+065.438+0.54%.
In 3.20 13 years, if China can maintain its existing international market share and expand it, considering the price factor, the annual export of APIs is expected to increase by 8%- 10%. In order to maintain rapid growth, pharmaceutical enterprises in China need to seek new development opportunities in the fields of characteristic APIs and biopharmaceuticals.
Baidu encyclopedia-medicine